Sure, this stock could go to double digits anytime as demonstrated in the past. That's a possible but there are 2 negatives that are almost certain. First, dilution. They have 6 quarters worth of cash at last quarter's burn rate. Companies never go below 4 quarters cash and the burn is increasing due to new hires. Second, Hillary will no doubt revisit her rhetoric regarding pharma pricing during the presidential campaign and we saw what that did to bio stock prices. I have other thoughts that keep me negative towards this company but at the risk of causing heart attacks among the true believers I'll keep those to myself. Short term trading vehicle is how I view this stock.GL
Stock purchase by CEO is a sign no buyout on the horizon.
"“any person purchasing or selling a security while in possession of material, nonpublic information shall be liable in an action in any court of competent jurisdiction…”
If I understand your cryptic reference to "in after out" you've been trading the stock instead of holding long?
You've been posting since Sept 9 2013 when the stock closed at $6.32. Forgive me if I don't follow your model established over the last 2 1/2 years.
Sold this morning @ $3.89. 14% in 4 trading days. Not on your "side" anymore. GL
Hey hey man! I just bought some shares this morning @ $3.39. I'm negative on the company since the Gensignia involvement of management and the fact that several tests have been available for use for 3 years and there is no real revenue but I am interested in making money. There will be a run up before dilution so I'm here for a trade. You and I are on the same side! For now.
What would prompt them to offer Erlander either side of $200,000 worth of stock to stay for 9 months? Was he about to jump ship? Seems sort of desperate.
PR says Erlander is presenting. Welch available for "one on one meetings", along with Erlander, after the presentation. Just another slide show.
Thanks for your reply. Another question I have regarding commercialization is just how does revenue get generated? Does this analysis require specialized equipment? Who manufactures it and who buys it? Is the model based on selling equipment and licensing the process? Does TROV think oncologists from all over the country are going to collect and ship urine samples then wait for results to be emailed when they are already drawing blood? How many samples could the lab process in a given period? Interesting to watch. Recent moves in management create uncertainty which is usually a bad thing for PPS.
Adams, Shuh, Zanibonu, Erlander all involved in executive roles at Gensignia while on the TROV payroll. Gensignia has a CLIA ladalso, or do they just use TROV's? This is the situation that turned me negative on TROV a couple of years ago. Was a good stock for tradng and may continuue to be but not a "truebeliever".
Could it be, just possibly, that after a year on the job Possard realized that commercialization would be a flop? Small pharmas amd bios often pay PPO's to be included on their lists. Maybe clarity apprars in upcoming 10Q.
First urine-based cancer mutation monitoring test available from Trovagene
SAN DIEGO, Oct. 1, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced availability of the first urine test for cancer mutation monitoring through the company's CLIA laboratory. The robustness of Trovagene's ultra-sensitive assay procedure has been demonstrated for detection of the BRAF V600E mutation from cell-free DNA in urine. This mutation commonly occurs in melanoma, as well as several other prevalent cancer types.
The Trovagene cell-free BRAF test is now available to healthcare providers for patient testing. Physicians interested in utilizing this test should contact Client Services at 888-391-7992.
SAN DIEGO, March 27, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), today announced the commercial availability of its urine-based HPV-HR (high-risk) assay, a molecular human papillomavirus (HPV) test. The non-invasive test is designed to accurately identify the presence or absence of 15 known high-risk HPV strains using proprietary DNA sequences.
The Trovagene HPV-HR test is available to patients through their healthcare providers. Physicians interested in utilizing the Trovagene assay should contact Client Services at 888-391-7992.
During 2013, we advanced our business with the following activities:
Made available the first urine-based cancer mutation monitoring test through our CLIA laboratory.
Announced the commercial availability of our urine-based human papillomavirus (HPV) test, which we plan to license to marketing partners on a global basis.
Ineffective sales force or hype?